Omberacetam

Nootropic Dipeptide (synthetic Peptide Analog Of Piracetam / NGF Mimetic)Rx: PrescriptionCompound: Approved

Also known as: GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Noopept, Noopeptide

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Omberacetam (brand name Noopept) is a synthetic dipeptide nootropic and neuroprotective compound approved in Russia for cognitive impairment and mild cognitive disorders. It is a prodrug that is metabolized to cycloprolylglycine, an endogenous neuropeptide. It enhances memory, learning, and attention while exhibiting neuroprotective properties. It is widely used as a research and self-administered nootropic compound in Western countries.

Mechanism of Action

Cycloprolylglycine mimetic and AMPA receptor positive modulator; also mimics nerve growth factor (NGF) effects by activating TrkA receptors and downstream signaling (MAPK/ERK, PI3K/Akt pathways); enhances glutamatergic neurotransmission and promotes neuroplasticity

Routes of Administration

IntranasalOralSublingual

Goals & Uses

  • Memory consolidationCognitiveModerate
  • NeuroprotectionNeurologyModerate
  • Alzheimer's disease symptomatic treatmentNeurodegenerationLow
  • Anxiety reductionNeuropsychiatricLow
  • Post-traumatic cognitive recoveryRehabilitationModerate
  • Cognitive enhancementNootropicModerate

Contraindications

  • Hypersensitivity to omberacetam or excipientsAllergyHigh
  • Severe hepatic impairmentOrganModerateLiver function concerns
  • Age under 18PediatricModerate
  • Severe renal impairmentOrganModerateKidney function concerns
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • LactationReproductiveHigh

Adverse Effects

  • HeadacheNeurologicUncommonPain in the head or upper neck
  • InsomniaPsychiatricUncommonDifficulty sleeping
  • Increased blood pressureCardiovascularUncommon
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Psychomotor agitationNeuropsychiatricRare
  • IrritabilityPsychiatricUncommonIncreased agitation or short temper

Drug Interactions

  • Psychostimulants (amphetamine, modafinil)Moderate
  • Cholinergic agentsLow
  • AlcoholModerate
  • AntihypertensivesLowMay potentiate hypotensive effects in some contexts

Population Constraints

  • Patients with hypertensionCardiovascularRelative
  • Patients with epilepsyNeurologicalRelative
  • Elderly patientsAgeRelative
  • Pediatric population (<18 years)PediatricAbsolute

Regulatory Status

  • European UnionUnapprovedNot approved by EMA; regulatory status varies by member state; generally sold as a supplement or research compound
  • United StatesUnapprovedNot FDA approved; sold as a research chemical or unscheduled dietary supplement; no IND or NDA on record
  • United KingdomUnapprovedNot MHRA approved; sold as unregulated supplement; not a controlled substance under UK law as of last review

Approved as a pharmaceutical drug in Russia (Novartis/Grunethal licensed to JSC Lekko Pharmaceuticals) for cognitive impairment associated with organic brain diseases and post-traumatic stress. Not approved by the FDA, EMA, or MHRA. Sold as an unregulated dietary supplement or research chemical in many Western markets.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack